Cancer Research Horizons

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

GBP pound sterling funding
#Biotech #Cancer Research Horizons #Cancer vaccine #Oncology #Start-ups #University of Oxford

Cancer vaccine developer secures £12.8m

Oxford University spin-out Infinitopes Precision Immunomics has completed a £12.8 ($16) million seed funding round led by Octopus Ventures. The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital,… Read More

#Business & Investment #News #Start-up Zone

#Bioprinting #Cancer research #Cancer Research Horizons #Cancer Research UK #Cell therapy #Data #Data management #Data security #Drug development #Drug discovery #Electronic Lab Notebooks (ELN) #Laboratory data #Oncology #Organ manufacturing #Start-ups #Tissue engineering

Podcast looks behind the scenes of the drug discovery industry

This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More

#News

Cancer Research
#Cancer research #Cancer Research Horizons #Precision medicine #Regulatory #Start-ups #Technology

Conversations from Cancer Research Horizons’ Innovation Summit 2023 

Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees.   Trends for cancer research  … Read More

#Cancer Research #Exclusive Content #Opinion #Regulatory

#Cancer research #Cancer Research Horizons #Cancer Research UK #Collaboration #Guardant Health #Precision medicine

CRUK and Guardant collaborate on precision cancer drugs

Cancer Research UK (CRUK), Cancer Research Horizons, and precision oncology company Guardant Health have launched a collaboration to advance cancer treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its… Read More

#Business & Investment #Cancer Research #News

Antibodies
#Antibody-based therapeutics #Cancer research #Cancer Research Horizons #Oncology #Synthetic libraries #Twist Bioscience

Partnership could enhance antibody discovery for cancer research

Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, a collection of synthesised antibody libraries designed based on naturally occurring sequences that… Read More

#Cancer Research #News

#Cancer research #Cancer Research Horizons #Interview

New podcast: Cancer research at the academic/industry interface

The latest sponsored DDW Sitting Down With podcast is now available for your listening pleasure. The podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer… Read More

#News

#Cancer research #Cancer Research Horizons #Interview #Sitting Down With #Sitting Down With podcast

How Cancer Research Horizons is innovating through its academic and industry interface

The latest sponsored DDW Sitting Down With podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer Research Horizons is conducting at its site in Newcastle University; how Cancer Research… Read More

#Podcasts

Cancer research lab
#Academic #Cancer #Cancer research #Cancer Research Horizons #Cancer Research UK #Collaboration #Oncology

Academic-industry collaboration extends cancer drug alliance 

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals.  The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, with the aim of providing an… Read More

#Cancer Research #News

#Cancer research #Cancer Research Horizons #Cancer Research UK #Drug development #Drug discovery #Oncology

New horizon for cancer innovation

Listen to this article on the DDW podcast: Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of… Read More

#Cancer Research #Exclusive Content